Form 4: Director Robert Bessler Sells 75,000 LifeStance Shares

Director Robert Bessler sold 75,000 shares of LifeStance Health Group, Inc. common stock via Rule 10b5-1 trading plans.

Summary

• Director Robert Bessler executed the sale of 75,000 shares of LifeStance Health Group, Inc. (LFST) common stock on May 7, 2026.
• The shares were sold at a weighted average price of $8.55 per share, with individual transaction prices ranging from $8.40 to $8.89.
• The sales were conducted through two entities: 37,500 shares via Vitthal LLC and 37,500 shares via Shama LLC.
• The transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is a routine administrative action for directors.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is typically used to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale represents a reduction in the director's indirect beneficial ownership of the company's equity.

Risks

• Continued divestment by company insiders may be perceived negatively by retail investors as a lack of long-term confidence in the current share price.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for liquidity and diversification, and does not necessarily reflect a change in the company's fundamental health or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives and directors to manage personal equity holdings while maintaining compliance with SEC regulations.

Related Party Transactions

• The reporting person disclaims beneficial ownership of securities held by Vitthal LLC, Shama LLC, and Alpine Glow Capital, except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the pre-planned nature of the sale mitigates concerns regarding potential non-public information usage.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

LifeStance Health, LFST, Insider Trading, Form 4, Director Sale, Equity